Medical Treatment: How and How Long?

  • R. A. Prinz
Conference paper


Normally, pancreatic secretions are produced by the acinar cells and move in a one way direction through the duct system to the duodenum. If glandular integrity is disrupted, pancreatic exocrine fluid may find another route of egress. There are three potential courses for the fluid to take. It may enter the peritoneal cavity directly and form pancreatic ascites. It may be walled off by surrounding tissue and form a pseudocyst. Finally, it may form a fistulous tract that terminates either internally or externally. This report reviews the medical management of external pancreatic fistulas.


Pancreatic Fistula Pancreatic Secretion Islet Cell Tumor Fistulous Tract Pancreatic Exocrine Secretion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zinner MJ, Baker RR, Cameron JL (1974) Pancreatic cutaneous fistulas. Surg Gynecol Obstet 138:710–712PubMedGoogle Scholar
  2. 2.
    Kellum JM, Holland GF, McNeill P (1988) Traumatic pancreatic fistula: comparison of enterai and parenteral feedings. J Trauma 28:700 – 704PubMedCrossRefGoogle Scholar
  3. 3.
    Martin FM, Rossi RL, Munson JL, ReMine SG, Braasch JW (1989) Management of pancreatic fistulas. Arch Surg 124:571–573PubMedCrossRefGoogle Scholar
  4. 4.
    Pederzoli P, Bassi C, Falconi M, Albrigo R, Vantini I, Micciolo R (1986) Conservative treatment of pancreatic fistulas with parenteral nutrition alone or in combination with continuous infusion of somatostatin, glucagon or calcitonin. Surg Gynecol Obstet 163 : 428–432PubMedGoogle Scholar
  5. 5.
    Baker RJ, Bass RT, Zajtchuk R, Strohl EL (1967) External pancreatic fistula following abdominal injury. Arch Surg 95:556 – 566PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson MD, Mueller JM, Snyder DO (1960) Depression of pancreatic exocrine secretion with a carbonic anhydrase inhibitor. Am J Dig Dis 5:714–723PubMedCrossRefGoogle Scholar
  7. 7.
    Craft CB (1938) The effect of ephedrine on pancreatic secretion: a method for the management of patients having pancreatic fistula. Surgery 4:64–73Google Scholar
  8. 8.
    Joehl RJ, Nahrwold DL (1985) Inhibition of human pancreatic secretion by terbutaline as a potential agent for treating patients with pancreatic fistula. Surg Gynecol Obstet 160: 109–114PubMedGoogle Scholar
  9. 9.
    Fallingborg J, Anderson SP, Laustsen J, Christensen LA (1986) Glucagon treatment of external pancreatic fistula. Acta Chir Scan 151:183 –184Google Scholar
  10. 10.
    Garcia-Puges AM, Navarro S, Fernandez-Cruz L, Ros E, Hinojosa L, Pera C (1988) Oral pancreatic enzymes accelerate closure of external pancreatic fistulae. Br J Surg 751924–925PubMedCrossRefGoogle Scholar
  11. 11.
    Morris SJ, Barkin JS, Kaiser MH, Haas MF (1979) Radiation therapy of a pancreatic fistula. Am J Gastroenterol 72:431 – 433PubMedGoogle Scholar
  12. 12.
    Ahren B, Tranberg KG, Bengmark S (1988) Treatment of pancreatic fistula with the somatostatin analogue SMS 201 – 995. Br J Surg 75:718PubMedCrossRefGoogle Scholar
  13. 13.
    Barnes SM, Kontny BG, Prinz RA (1993) Somatostatin analog treatment of pancreatic fistulas. Int J Pancreatol 14:181 –188PubMedGoogle Scholar
  14. 14.
    de Bois MH, Bosman CH, de Graaf P, van Hoogenhuijze J (1988) Closure of a high-output external pancreatic fistula by SMS 201–995, a long-acting analogue of somatostatin. Neth J Med 32:293 – 297PubMedGoogle Scholar
  15. 15.
    Kwan D, Aufses AH (1989) Short-term administration of SMS 201 – 995 in the management of an external pancreatic fistula. Am J Gastroenterol 84:326–328PubMedGoogle Scholar
  16. 16.
    Lansden FT, Adams DB, Anderson MC (1989) Treatment of external pancreatic fistulas with somatostatin. Am Surg 55:695 – 698PubMedGoogle Scholar
  17. 17.
    Prinz RA, Pickleman J, Hoffman JP (1988) Treatment of pancreatic cutaneous fistula with a somatostatin analog. Am J Surg 155:36–42PubMedCrossRefGoogle Scholar
  18. 18.
    Doubilet H, Fishman L (1961) Human biliary-pancreatic secretion. Am J Gastroent 35:499PubMedGoogle Scholar
  19. 19.
    Sinclair ISR (1956) Observations on a case of external pancreatic fistula in man. Br. J Surg 44:250PubMedCrossRefGoogle Scholar
  20. 20.
    Birnbaum D, Hollander F (1952) Inhibition of pancreatic secretion by the carbonic anhydrase inhibitor, 2-acetylamino-1,3,4-thiazol-5-sulfonamide. Proc Soc Exp Biol Med 81:23PubMedGoogle Scholar
  21. 21.
    Papastrat CJ, Miller JM (1958) Treatment of external pancreatic fistula with diamox. Am J Dig Dis 3:399PubMedCrossRefGoogle Scholar
  22. 22.
    Watman RN (1956) The inhibition of human pancreatic secretion by carbonic anhydrase inhibitor. Surgery 39:337PubMedGoogle Scholar
  23. 23.
    Rudick J, Gonda M, Rosenberg IR et al. (1973) Effects of a beta-adrenergic receptor stimulant (isoproterenol) on pancreatic exocrine secretion. Surgery 74:338–343PubMedGoogle Scholar
  24. 24.
    Joehl RJ, Nahrwold DL (1985) Inhibition of human pancreatic secretion by terbutaline as a potential agent for treating patients with pancreatic fistula. Surg Gynecol Obstet 160: 109–114PubMedGoogle Scholar
  25. 25.
    Knight MJ, Condon JR, Smith R (1971) Possible use of glucagon in the treatment of pancreatitis. Br J Med 2:440CrossRefGoogle Scholar
  26. 26.
    Fallingborg J, Andersen SP, Laustsen J, Christensen LA (1985) Glucagon treatment of external pancreatic fistula. Acta Chir Scand 151:183–184PubMedGoogle Scholar
  27. 27.
    Hughes RG, Cooper MJ, Wiliamson RCN (1983) Conservative management of post-traumatic pancreatic fistula. Scand J Gastroenterol 18 [Suppl 87] : 103Google Scholar
  28. 28.
    Owyang CS, Louie D, Tatum D (1986) Feedback regulation of pancreatic enzyme secretion. Supression of cholecystokinin release by trypsin. J Clin Invest 77:2042–2047PubMedCrossRefGoogle Scholar
  29. 29.
    Reichlin S (1983) Somatostatin. N Engl J Med 309:1556 –1563PubMedCrossRefGoogle Scholar
  30. 30.
    Conway DR, Djuricin G, Prinz RA (1988) The effect of somatostatin analogue (SMS 201–995) on pancreatic blood flow. Surgery 104 (6) 11024–1030Google Scholar
  31. 31.
    Hild P, Stoyanov M, Dobroschke J, Aigner K (1982) La somatostatine dans le traitement medical des distules du pancreas et de l’intestin grele. Ann Cir 36 (3) : 193 –196Google Scholar
  32. 32.
    Cavagni F, Pinto M, Castagna L (1984) Protracted administraton of somatostatin to patients with pancreatic fistulas: clinical and endocrine evaluation. In: Angelini L, Usadel KM (eds) Therapeutic effects of somatostatin. Scrono Symposia Reviews, Rome, pp 157–165Google Scholar
  33. 33.
    Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Betcher TJ, Pless J (1982) SMS 201–995: a very potent and selectiveoctapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140PubMedCrossRefGoogle Scholar
  34. 34.
    Ellison EC, O’Dorisio TM, Lott J, Beaver B, Cloutier CT, Carey LC (1985) The effect of long-acting somatostatin analog (SMS 201–995) on basal pancreatic exocrine secretion in man. Gastroenterology 88:1373 –1374Google Scholar
  35. 35.
    Williams ST, Weltering EA, O’Dorisio TM, Fletcher WS (1989) Effect of octreotide acetate on pancreatic exocrine funtion. Am J Surg 157:459–462PubMedCrossRefGoogle Scholar
  36. 36.
    Altimari AF, Bhoopalam N, O’Dorisio T, Lange CL, Sandberg L, Prinz RA (1986) Use of a somatostatin analog (SMS 201–995) in the glucagonoma syndrome. Surgery 100:989 – 996PubMedGoogle Scholar
  37. 37.
    Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang SL, Clineschmidt BC (1987) In vivo pharmacology of L-364, 718, a new potent non peptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 241:103 –109PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • R. A. Prinz

There are no affiliations available

Personalised recommendations